PDS End Period Cash Flow vs Change In Cash Analysis

PDSB Stock

USD 2.19 0.04 1.86%

PDS Biotechnology financial indicator trend analysis is much more than just breaking down PDS Biotechnology Corp prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether PDS Biotechnology Corp is a good investment. Please check the relationship between PDS Biotechnology End Period Cash Flow and its Change In Cash accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PDS Biotechnology Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

End Period Cash Flow vs Change In Cash

End Period Cash Flow vs Change In Cash Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of PDS Biotechnology Corp End Period Cash Flow account and Change In Cash. At this time, the significance of the direction appears to have weak relationship.

The correlation between PDS Biotechnology's End Period Cash Flow and Change In Cash is 0.31. Overlapping area represents the amount of variation of End Period Cash Flow that can explain the historical movement of Change In Cash in the same time period over historical financial statements of PDS Biotechnology Corp, assuming nothing else is changed. The correlation between historical values of PDS Biotechnology's End Period Cash Flow and Change In Cash is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which End Period Cash Flow of PDS Biotechnology Corp are associated (or correlated) with its Change In Cash. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Change In Cash has no effect on the direction of End Period Cash Flow i.e., PDS Biotechnology's End Period Cash Flow and Change In Cash go up and down completely randomly.

Correlation Coefficient

0.31

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

End Period Cash Flow

Change In Cash

Most indicators from PDS Biotechnology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into PDS Biotechnology Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PDS Biotechnology Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

At present, PDS Biotechnology's Issuance Of Capital Stock is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 309.2 M, whereas Selling General Administrative is forecasted to decline to about 11.7 M.

	2021	2022	2023	2024 (projected)
Interest Expense	4.3K	1.3M	4.2M	4.4M
Depreciation And Amortization	246.4K	49.1K	57.3K	54.5K

Interest Expense Depreciation And Amortization

PDS Biotechnology fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Short Long Term Debt Total	Current Deferred Revenue	Short Term Debt	Other Assets
Total Assets		0.59	0.71	0.96	0.76	-0.97	-0.52	0.44	1.0	0.74	0.06	1.0	-0.61	0.8	0.22	-0.3	0.3	0.82	-0.02	0.77	1.0	0.8	0.55	0.11	0.43	-0.32
Other Current Liab	0.59		0.69	0.53	0.34	-0.49	-0.74	0.15	0.59	0.33	0.1	0.59	-0.6	0.72	0.32	-0.15	0.49	0.76	0.11	0.34	0.59	0.73	0.59	0.0	0.21	-0.3
Total Current Liabilities	0.71	0.69		0.58	0.49	-0.55	-0.79	0.68	0.7	0.48	0.03	0.7	-0.62	0.8	0.42	-0.03	0.54	0.81	0.32	0.52	0.71	0.8	0.86	0.55	0.72	-0.36
Total Stockholder Equity	0.96	0.53	0.58		0.67	-0.97	-0.48	0.32	0.96	0.65	-0.04	0.96	-0.63	0.8	0.2	-0.55	0.3	0.82	-0.29	0.68	0.96	0.81	0.36	0.03	0.33	-0.15
Property Plant And Equipment Net	0.76	0.34	0.49	0.67		-0.77	-0.3	0.26	0.76	1.0	0.58	0.76	-0.4	0.44	-0.32	0.02	-0.07	0.56	0.13	1.0	0.75	0.45	0.37	-0.19	0.19	-0.22
Net Debt	-0.97	-0.49	-0.55	-0.97	-0.77		0.39	-0.24	-0.97	-0.75	-0.11	-0.97	0.54	-0.73	-0.06	0.39	-0.18	-0.75	0.2	-0.77	-0.97	-0.73	-0.34	0.06	-0.26	0.25
Retained Earnings	-0.52	-0.74	-0.79	-0.48	-0.3	0.39		-0.53	-0.52	-0.3	-0.17	-0.52	0.62	-0.82	-0.37	0.28	-0.39	-0.89	-0.09	-0.32	-0.52	-0.83	-0.58	-0.44	-0.55	0.36
Accounts Payable	0.44	0.15	0.68	0.32	0.26	-0.24	-0.53		0.43	0.25	-0.15	0.43	-0.39	0.44	0.53	0.06	0.36	0.44	0.47	0.29	0.44	0.45	0.66	0.83	0.92	-0.28
Cash	1.0	0.59	0.7	0.96	0.76	-0.97	-0.52	0.43		0.74	0.06	1.0	-0.6	0.8	0.22	-0.31	0.3	0.82	-0.02	0.77	1.0	0.8	0.54	0.11	0.43	-0.32
Non Current Assets Total	0.74	0.33	0.48	0.65	1.0	-0.75	-0.3	0.25	0.74		0.61	0.74	-0.38	0.42	-0.35	0.04	-0.09	0.55	0.14	1.0	0.73	0.43	0.36	-0.21	0.18	-0.23
Non Currrent Assets Other	0.06	0.1	0.03	-0.04	0.58	-0.11	-0.17	-0.15	0.06	0.61		0.06	0.05	-0.07	-0.71	0.38	-0.49	0.13	0.26	0.57	0.05	-0.07	-0.06	-0.38	-0.21	-0.36
Cash And Short Term Investments	1.0	0.59	0.7	0.96	0.76	-0.97	-0.52	0.43	1.0	0.74	0.06		-0.6	0.8	0.22	-0.31	0.3	0.82	-0.02	0.77	1.0	0.8	0.54	0.11	0.43	-0.32
Net Receivables	-0.61	-0.6	-0.62	-0.63	-0.4	0.54	0.62	-0.39	-0.6	-0.38	0.05	-0.6		-0.74	-0.45	0.4	-0.78	-0.72	0.13	-0.41	-0.61	-0.75	-0.36	-0.23	-0.33	-0.15
Common Stock Total Equity	0.8	0.72	0.8	0.8	0.44	-0.73	-0.82	0.44	0.8	0.42	-0.07	0.8	-0.74		0.5	-0.47	0.52	0.95	-0.15	0.45	0.8	1.0	0.57	0.33	0.44	-0.25
Common Stock Shares Outstanding	0.22	0.32	0.42	0.2	-0.32	-0.06	-0.37	0.53	0.22	-0.35	-0.71	0.22	-0.45	0.5		-0.19	0.72	0.29	0.13	-0.3	0.23	0.5	0.48	0.65	0.48	-0.07
Non Current Liabilities Total	-0.3	-0.15	-0.03	-0.55	0.02	0.39	0.28	0.06	-0.31	0.04	0.38	-0.31	0.4	-0.47	-0.19		-0.21	-0.46	0.87	0.02	-0.31	-0.48	0.26	0.05	-0.03	-0.42
Other Current Assets	0.3	0.49	0.54	0.3	-0.07	-0.18	-0.39	0.36	0.3	-0.09	-0.49	0.3	-0.78	0.52	0.72	-0.21		0.4	0.01	-0.06	0.31	0.51	0.48	0.45	0.3	0.24
Other Stockholder Equity	0.82	0.76	0.81	0.82	0.56	-0.75	-0.89	0.44	0.82	0.55	0.13	0.82	-0.72	0.95	0.29	-0.46	0.4		-0.12	0.57	0.82	0.96	0.56	0.26	0.46	-0.3
Total Liab	-0.02	0.11	0.32	-0.29	0.13	0.2	-0.09	0.47	-0.02	0.14	0.26	-0.02	0.13	-0.15	0.13	0.87	0.01	-0.12		0.15	-0.02	-0.14	0.56	0.37	0.4	-0.56
Property Plant And Equipment Gross	0.77	0.34	0.52	0.68	1.0	-0.77	-0.32	0.29	0.77	1.0	0.57	0.77	-0.41	0.45	-0.3	0.02	-0.06	0.57	0.15		0.76	0.46	0.39	-0.16	0.22	-0.23
Total Current Assets	1.0	0.59	0.71	0.96	0.75	-0.97	-0.52	0.44	1.0	0.73	0.05	1.0	-0.61	0.8	0.23	-0.31	0.31	0.82	-0.02	0.76		0.81	0.55	0.12	0.43	-0.32
Common Stock	0.8	0.73	0.8	0.81	0.45	-0.73	-0.83	0.45	0.8	0.43	-0.07	0.8	-0.75	1.0	0.5	-0.48	0.51	0.96	-0.14	0.46	0.81		0.58	0.33	0.46	-0.25
Short Long Term Debt Total	0.55	0.59	0.86	0.36	0.37	-0.34	-0.58	0.66	0.54	0.36	-0.06	0.54	-0.36	0.57	0.48	0.26	0.48	0.56	0.56	0.39	0.55	0.58		0.53	0.6	-0.41
Current Deferred Revenue	0.11	0.0	0.55	0.03	-0.19	0.06	-0.44	0.83	0.11	-0.21	-0.38	0.11	-0.23	0.33	0.65	0.05	0.45	0.26	0.37	-0.16	0.12	0.33	0.53		0.79	-0.21
Short Term Debt	0.43	0.21	0.72	0.33	0.19	-0.26	-0.55	0.92	0.43	0.18	-0.21	0.43	-0.33	0.44	0.48	-0.03	0.3	0.46	0.4	0.22	0.43	0.46	0.6	0.79		-0.3
Other Assets	-0.32	-0.3	-0.36	-0.15	-0.22	0.25	0.36	-0.28	-0.32	-0.23	-0.36	-0.32	-0.15	-0.25	-0.07	-0.42	0.24	-0.3	-0.56	-0.23	-0.32	-0.25	-0.41	-0.21	-0.3

Click cells to compare fundamentals

PDS Biotechnology Account Relationship Matchups

PDS Biotechnology fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	14.5M	30.9M	67.2M	77.0M	59.4M	64.9M
Other Current Liab	1.6M	1.7M	2.2M	8.3M	2.4M	3.7M
Total Current Liabilities	2.8M	3.3M	3.8M	9.8M	13.6M	7.3M
Total Stockholder Equity	11.7M	27.1M	63.2M	44.0M	26.1M	43.3M
Property Plant And Equipment Net	21.1K	553.1K	357.7K	527.5K	335.0K	318.3K
Net Debt	(12.2M)	(28.2M)	(64.8M)	(50.3M)	(32.7M)	(34.3M)
Retained Earnings	(28.9M)	(43.8M)	(60.7M)	(101.6M)	(144.5M)	(137.3M)
Accounts Payable	1.2M	1.4M	1.3M	1.2M	7.0M	7.3M
Cash	12.2M	28.8M	65.2M	73.8M	56.6M	61.8M
Non Current Assets Total	21.1K	553.1K	357.7K	527.5K	335.0K	318.3K
Cash And Short Term Investments	12.2M	28.8M	65.2M	73.8M	56.6M	61.8M
Common Stock Total Equity	10.6K	1.7K	7.3K	10.0K	11.4K	7.5K
Common Stock Shares Outstanding	4.9M	16.7M	25.6M	28.6M	31.0M	32.5M
Liabilities And Stockholders Equity	14.5M	30.9M	67.2M	77.0M	59.4M	64.9M
Non Current Liabilities Total	1.2M	490.4K	231.4K	23.2M	19.6M	10.4M
Other Current Assets	2.3M	1.5M	1.6M	2.7M	2.5M	1.6M
Other Stockholder Equity	40.6M	70.9M	123.9M	145.6M	170.6M	136.7M
Total Liab	2.8M	3.8M	4.0M	33.0M	33.3M	34.9M
Property Plant And Equipment Gross	21.1K	553.1K	357.7K	527.5K	467.8K	444.4K
Total Current Assets	14.5M	30.3M	66.8M	76.5M	59.1M	63.4M
Common Stock	1.7K	7.3K	9.4K	10.0K	10.9K	8.1K
Other Assets	11.5K	12.8K	547.7K	1.0	1.15	1.09
Capital Surpluse	222.6M	40.6M	70.9M	145.6M	131.0M	122.2M
Property Plant Equipment	21.1K	553.1K	357.7K	527.5K	474.8K	438.1K
Net Tangible Assets	11.7M	27.1M	63.2M	44.0M	50.6M	53.1M
Net Invested Capital	11.7M	27.1M	63.2M	67.0M	49.8M	52.1M
Net Working Capital	11.7M	27.1M	63.1M	66.7M	45.4M	50.2M
Capital Stock	1.7K	7.3K	9.4K	10.0K	10.9K	9.2K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

When determining whether PDS Biotechnology Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of PDS Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pds Biotechnology Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pds Biotechnology Corp Stock:

How To Invest In PDS

Details

Is PDS Stock a good investment?

Details

What is PDS Biotechnology's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PDS Biotechnology Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PDS Biotechnology. If investors know PDS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PDS Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.17)

Return On Assets

(0.40)

Return On Equity

(1.28)

The market value of PDS Biotechnology Corp is measured differently than its book value, which is the value of PDS that is recorded on the company's balance sheet. Investors also form their own opinion of PDS Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is PDS Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PDS Biotechnology's market value can be influenced by many factors that don't directly affect PDS Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between PDS Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if PDS Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PDS Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

PDS End Period Cash Flow vs Change In Cash Analysis

End Period Cash Flow vs Change In Cash

End Period Cash Flow vs Change In Cash Correlation Analysis

Correlation Coefficient

End Period Cash Flow

Change In Cash

PDS Biotechnology fundamental ratios Correlations

PDS Biotechnology Account Relationship Matchups

High Positive Relationship

High Negative Relationship

PDS Biotechnology fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Cash And Short Term Investments	+ 1.0	Cash

Total Current Assets	- 0.97	Net Debt
Cash And Short Term Investments	- 0.97	Net Debt
Cash	- 0.97	Net Debt
Net Debt	- 0.97	Total Stockholder Equity
Net Debt	- 0.97	Total Assets
Other Stockholder Equity	- 0.89	Retained Earnings